Innate Pharma (IPHA) Expected to Announce Quarterly Earnings on Wednesday

Innate Pharma (NASDAQ:IPHA) will likely be issuing its Q1 2026 TU results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.3492) per share and revenue of $2.7160 million for the quarter. Interested persons can check the company’s upcoming Q1 2026 TU earning summary page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 7:30 AM ET.

Innate Pharma (NASDAQ:IPHA) last announced its quarterly earnings results on Saturday, February 14th. The company reported ($0.18) earnings per share (EPS) for the quarter. The business had revenue of $2.41 million during the quarter. On average, analysts expect Innate Pharma to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Innate Pharma Price Performance

Shares of Innate Pharma stock opened at $1.40 on Wednesday. Innate Pharma has a 52 week low of $1.17 and a 52 week high of $2.63. The stock has a 50 day moving average price of $1.47 and a two-hundred day moving average price of $1.71.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. BTIG Research initiated coverage on Innate Pharma in a report on Thursday, March 12th. They issued a “buy” rating and a $8.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $5.00 price target on shares of Innate Pharma in a research note on Tuesday, April 7th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Innate Pharma in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $5.00.

Institutional Trading of Innate Pharma

Several institutional investors and hedge funds have recently made changes to their positions in IPHA. Jane Street Group LLC bought a new position in shares of Innate Pharma during the fourth quarter valued at about $162,000. Millennium Management LLC purchased a new position in Innate Pharma during the fourth quarter worth about $36,000. Finally, OLD Mission Capital LLC bought a new stake in Innate Pharma in the 4th quarter worth about $50,000. Hedge funds and other institutional investors own 0.16% of the company’s stock.

Innate Pharma Company Profile

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.